66 citations,
January 2001 in “Vitamins and hormones” Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.
7 citations,
April 2019 in “The Journal of Steroid Biochemistry and Molecular Biology” 11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.
2 citations,
November 2017 in “Elsevier eBooks” Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
May 2018 in “The Journal of urology/The journal of urology” The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.
2 citations,
December 2021 in “International Journal of Andrology” Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
46 citations,
March 2001 in “Journal of endocrinological investigation” 5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
44 citations,
January 1999 in “Advances in pharmacology” The document concludes that the androgen receptor's structure and function are complex, affecting how it regulates genes and is involved in diseases like prostate cancer.
5 citations,
December 2021 in “Physiological Research” Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.
2 citations,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
November 2022 in “Scientific Data” The research identified genes and non-coding RNAs in cells that could be affected by testosterone, which may help understand hair loss and prostate cancer.
451 citations,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
218 citations,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
61 citations,
May 2010 in “Integrative Cancer Therapies” There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
28 citations,
July 2017 in “Journal of Endocrinological Investigation” Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.
26 citations,
March 2006 in “Endocrine, metabolic & immune disorders. Drug targets” This enzyme helps metabolize fatty acids and isoleucine, and could be key in treating neurological diseases and certain cancers.
16 citations,
October 2007 in “Andrologia” DHT is a strong androgen that may pose less risk to the prostate compared to testosterone.
14 citations,
February 1994 in “Tetrahedron Letters” Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.
7 citations,
January 2016 in “British Journal of Cancer” Men with certain types of baldness at age 45 may have a higher risk of colon cancer and colorectal adenoma.
2 citations,
April 2007 in “Journal of Labelled Compounds and Radiopharmaceuticals” The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.
1 citations,
May 2001 in “Pharmacology & Toxicology” Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
1 citations,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
February 2012 in “Community oncology” The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.
October 2015 in “Elsevier eBooks” Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.